Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 Association between montelukast use and risk of different out-comes (significantly protective hazard ratios in bold)a

From: Prescription database analyses indicates that the asthma medicine montelukast might protect against dementia: a hypothesis to be verified

Study group

Cases/Total (%)

Hazard ratios (95% CI)

Montelukast pos

Montelukast neg

Ageb

Unadjusted

Adjusted

Dementia medicinec

489/23,521 (2.1)

4967/178,884 (2.9)

>60

0.94 (0.85–1.03)

0.89 (0.81–0.98)

Nursing homed

507/23,634 (2.2)

5459/179,768 (3.1)

60–75

0.65 (0.57–0.74)

0.67 (0.59–0.77)

>75

1.00 (0.88–1.13)

0.99 (0.87–1.13)

Deathd

5512/23,634 (30.4)

55,857/179,768 (45.1)

60–75

0.86 (0.82–0.89)

0.64 (0.61–0.67)

>75

0.95 (0.92–0.98)

0.81 (0.78–0.84)

Parkinson’s medicinee

691/23,371 (3.0)

4550/178,134 (2.6)

>60

1.21 (1.12–1.32)

1.06 (0.98–1.15)

Diabetes medicinee

1523/22,270 (7.3)

11,247/170,157 (7.1)

>60

1.01 (0.96–1.07)

0.85 (0.80–0.90)

  1. aThe hazard ratios are based on comparing subjects using montelukast with those using only inhaling corticosteroids. The adjusted ratios are adjusted for sex, receiving drugs for heart conditions, and having a high consumption of drugs during the follow up period. The discrepancies between the sum of users in each analysis, and the grand total of 203,473 in Table 1, are due to truncations. The total number of person-years follow-up was between 1,346,308 and 1,480,476 (average 7.0–7.3 years per subject)
  2. bAs of 2014
  3. cThe adjusted analysis was stratified on having a high consumption of drugs dispensed per day, because this covariate did not meet the proportional hazards assumption
  4. dAs the effect of montelukast did not meet the proportional hazards assumption, the model was fitted by splitting into two age-periods, 60–75 years and >75 years
  5. eThe adjusted analysis was stratified on having a high consumption of drugs dispensed per day, and prescription of cardiovascular medicine, because these covariates did not meet the proportional hazards assumption
Back to article page

Immunity & Ageing

ISSN: 1742-4933

Contact us